Article thumbnail

Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival

By Miriam A. Lynn, Jason Kindrachuk, Alexandra K. Marr, Håvard Jenssen, Nelly Panté, Melissa R. Elliott, Scott Napper, Robert E. Hancock and W. Robert McMaster


Protozoan parasites are the causative agent of much disease in tropical areas of the world. Currently, the control of these diseases is dependent on outdated drug treatment, with associated high toxicity and drug resistance. There is an urgent need for novel anti-parasitic therapies. One emerging anti-parasitic therapies is Host defence peptides (HDPs). Here we test the HDP BMAP-28 as an anti-leishmanial therapy against two lifecycle stages of Leishmania major, the promastigotes (insect infective form) and the intracellular amastigote (mammalian infective form). Two stereoisomers of BMAP-28, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), were also tested for anti-leishmanial activity. The BMAP-28 form (L-form) was susceptible to degradation by GP63, the metalloproteinase that covers the promastigotes cell surface. However, the BMAP-28 isomers, the D-form and RI-form were resistant, and therefore more potent against the promastigote parasite. Though other anti-leishmanial HDP studies focus on the promastigote form of the parasite, it is the mammalian infective form, the amastigote, which causes the disease symptoms. Here we demonstrate that BMAP-28 and its isomers D-BMAP-28 and RI-BMAP-28 are effective against the amastigote form of the parasite using a macrophage infection model. These findings show that BMAP-28 has excellent potential as a novel anti-leishmanial therapeutic

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells.
  2. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.
  3. (2009). Antimicrobial peptide-induced apoptotic death of leishmania results from calcium-de pend ent, caspase-independent mitochondrial toxicity.
  4. (2009). Antiplasmodial and antileishmanial activities of phylloseptin-1, an antimicrobial peptide from the skin secretion of Phyllomedusa azurea (Amphibia).
  5. (2005). Bactericidal and antiendotoxic properties of short cationic peptides derived from a snake venom Lys49 phospholipase A2.
  6. (2008). BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection.
  7. (2002). BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore.
  8. (2006). Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide.
  9. (2007). Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections.
  10. (1989). Characterization of the promastigote surface protease of Leishmania as a membrane-bound zinc endopeptidase.
  11. (2002). Chemotherapy of leishmaniasis.
  12. (2006). Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.
  13. (1986). Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.
  14. (2006). Development of a semi-automated colorimetric assay for screening anti-leishmanial agents.
  15. (2010). Drug Resistance in Leishmaniasis.
  16. (2006). Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H.
  17. (2003). Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides.
  18. (2008). Fibronectin binding and proteolytic degradation by Leishmania and effects on macrophage activation.
  19. (2008). Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmania.
  20. (2005). Immunomodulatory activities of small host defense peptides.
  21. (2003). In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs.
  22. (2000). Interaction between heat shock proteins and antimicrobial peptides.
  23. (1986). Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin.
  24. (2003). Killing of African trypanosomes by antimicrobial peptides.
  25. (2009). Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoS Negl Trop Dis 3:
  26. (2009). Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases.
  27. (1990). Leishmania mexicana mexicana gp63 is a site-specific neutral endopeptidase.
  28. (2008). Leishmania surface protein gp63 binds directly to human natural killer cells and inhibits proliferation.
  29. (2006). LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.
  30. (1998). Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions.
  31. (1998). Mechanism of antimicrobial action of indolicidin.
  32. (1986). Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of leishmania-macrophage binding.
  33. (2003). Mor A
  34. (1986). Mucosal leishmaniasis (‘‘espundia’’ Escomel,
  35. (2008). Neutrophil-derived defensins as modulators of innate immune function.
  36. (1994). Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus.
  37. (1990). Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania.
  38. (2006). Pretreatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection.
  39. (2007). Protein turnover and differentiation in Leishmania.
  40. (2004). Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice.
  41. (2006). RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis.
  42. (2004). Role of positional hydrophobicity in the leishmanicidal activity of magainin 2.
  43. (1995). Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis.
  44. (1997). Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study.
  45. Stability, toxicity and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers.
  46. (2001). Stage-specific expression in Leishmania conferred by 39 untranslated regions of L. major leishmanolysin genes (GP63).
  47. (1991). Substrate-dependent pH optima of gp63 purified from seven strains of Leishmania.
  48. (2002). Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor.
  49. (2006). Temporins, anti-infective peptides with expanding properties.
  50. (2001). The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding.
  51. (2004). The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis.
  52. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.
  53. (1993). The effect of ongoing protein synthesis on the steady state levels of Gp63 RNAs in Leishmania chagasi.
  54. (2009). The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation.
  55. (1986). The major surface protein of Leishmania promastigotes is a protease.
  56. (2006). The major surface-metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing.
  57. (2007). The molecular basis of Leishmania pathogenesis.
  58. (1998). The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1– 8)M(1–18), a synthetic cecropin A-melittin hybrid peptide.
  59. (1980). Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells.